Cyborg MAD CATZ R.A.T. 3 (Unboxing and review)
Today we will be looking at the Cyborg MAD CATZ R.A.T 3 and remember to leave a like comment and a subscribe. Hope I helped you all out by making this video. If you would like to buy it: http://ad...
By: Howie PlaysGames
Read more from the original source:
Dreams by Cyborg
Dreams by Cyborg Music used:Nilow-Neapolitan Dreams by Lisa Mitchell.
By: ItsTheCyborg
Follow this link:
SEA coalers have been allowed back on to Hartlepool beaches.
Before Hartlepool Borough Council banned motorised vehicles from the town's beaches earlier this year about 19 people would collect washed up coal and sell it on.
But now Marjorie James, chairwoman of the council's neighbourhood services committee, has revealed the restriction has now been lifted.
The council, which leases the beaches from The Crown Estate, took the decision to block access pending the outcome of an application to vary its lease to allow sea coalers to take their vehicles on to the beaches.
Without such a variation, the council feared sea coalers would be trespassing on the beaches rendering their insurance invalid and making it illegal to allow them access.
But now agents for The Crown Estate have confirmed that they are minded to grant a lease variation and Cllr James has agreed to remove locks from barriers at several access points to allow sea coalers vehicles on to beaches, subject to the introduction of a local licensing scheme.
Gary Jackson, 26, a representative of the local sea coal trade said said he was "over the moon."
Mr Jackson, who runs his own health and safety training company, said generations of his own family had been involved in the sea coal and coal trade, said: "For many of the current sea coalers there is no other path for them to go down, sea coaling is their life. Im glad that the issue has now been resolved and Id like to thank the council for chasing up matters with the Crown Estates.
Cllr James said: "The councils decision to prevent sea coalers from gaining access to the beaches was taken earlier this year on legal advice and it was designed to protect the sea coalers themselves, members of the public and the council.
It was only ever intended to be a temporary measure, but it has taken a lot longer than expected to get to the point where we have been able to allow the sea coalers to return to the beaches.
Read the original here:
Minecraft: Space Astronomy- Episode 1: Let the Tree Punching Commence!
Let #39;s try out this new modpack from MJRLegends: Space Astronomy. Using the latest technology, we will explore different planets and find an answer to if the moon really is made of cheese. ...
By: l33tjedi
Read this article:
Minecraft: Space Astronomy- Episode 1: Let the Tree Punching Commence! - Video
The Chimney Swifts - Astronomy (Original Song)
http://music.cbc.ca/#!/artists/The-Chimney-Swifts - Local CBC Searchlight contestants the Chimney Swifts performing their original song Astronomy. Remember to cast them a vote every day until...
By: The Chimney Swifts
Read the rest here:
By Tony Hoffman
Pocket Universe: Virtual Sky Astronomy is an iPad app geared to newcomers to astronomy. It includes the usual planetarium view, showing the constellations in their proper positions relative to each other in the direction your iPad is pointing for any given time and location. It also features star and constellation quizzes, a solar system view that shows the planets in motion around the Sun, a section featuring individual 3D planets that you can spin, a section with astronomy news items, and more. The planetarium part of the app works okay, though it's rather basic, and some of the sections are amateurishly produced.
The app can be used in either Landscape or Portrait mode. After a brief, yet fun, animation (a fly-through of the solar system), the Home screenwhich changes color depending on the time of day you activate the appappears. The app's title appears at top center, and below it is an image of the Moon. Listed further down is the current date, the Julian date (a continuous count of days since the beginning of the Julian Period on January 1, 4713 BC, a measure frequently used by astronomers), the Star Date (in a nod to Star Trek, though there is no universally recognized conversion scheme between the TV series's Star Date chronology and actual time), and the lunar phase (Waxing Gibbous, when I tested the app). Below these bits of information, the rising and setting times of the Sun, Moon, and the planets that can be seen by the naked eye are listed.
Gaze into a Virtual Sky Appearing lower on the Home Screen are links marked Help, Virtual Sky and Extras, Planets, Orrery, What's Up?, and Ask. The heart of Pocket Universe, as it is with any planetarium program, is the Virtual Sky view, which lets you see the stars and constellations on your iPad's screen as they would actually appear in the night sky in whatever direction you point your device. It identifies constellations and bright stars both onscreen and via audio when they pass through the virtual crosshairs at the screen's center. Virtual Sky provides position and brightness data for the brightest stars, but no information on the vast majority of stars, which is unusual in a planetarium program.
The Extras section includes quizzes, depictions of the positions of Jupiter's and Saturn's brightest moons, 360-degree virtual views of the surfaces of the Moon and Mars, and more. While the latter items are good, the quizzes tended to be repetitive, asking some of the same questions over and over even when I got them right.
Tracking the Planets Clicking on What's Up? takes you to a table showing the altitude (in increments of 10 degrees) and azimuth (its compass direction, measured clockwise from due north) of the five planets you can see with the naked eye (Mercury, Venus, Mars, Jupiter, and Saturn), plus the Sun and Moon for a given location and date. At the bottom of the screen are right and left arrow buttons, plus a play/pause button, that let you view, speed up, pause, or reverse the motion of the planets over time.
The Help button takes you to a menu with five items. What's New shows you what has been changed in the current version of the app as opposed to the previous one. Getting Started teaches you some basics about the app. For instance, it tells you that the app can run on an iPhone, iPod, and iPad (I tested it on an iPad Air 2 ), provides a virtual sky view rendered for your location and time, and displays the 10,000 brightest stars, the location of the planets, Sun, and Moon, and the Messier catalogue of deep-sky objects.
The Planets section shows 3D rotating versions of the Sun, Moon, and our solar system's planets (Pluto is omitted), and includes basic data on each world. When you use the app in daytime, Earth is illuminated, but when you use it at night, our planet is in darkness, with just the faint outline of continents and the lights of cities. The globes vary greatly in quality; the Moon shows some detail on both its near side and far side, and Mars, Neptune, and Venus look fairly realistic (and Venus correctly rotating backwards). In contrast, the Sun appears as a glaring ball of mottled yellow and white, with sunspots looking like they were photoshopped in place, and Mercury appearing blotchy and nearly featureless. Forward and backward arrow buttons at the bottom of the screen take you from one planet to the next. Some basic detail is provided for each planet, including its rising and setting times in our sky, radius, distance from the Sun, period of rotation, orbital period, and number of satellites.
The Orrery view shows the solar system in motion, and can be tilted, squeezed, or pinched to change perspective. Through the use of front-arrow, back-arrow, and pause keys, you can freeze, speed up, or reverse the motion of the planets. The individual worlds are not identified in the Orrery view, although they're the same 3D planets that appear in the Planets section.
More:
SOURCE: American Society for Radiation Oncology
FAIRFAX, VA--(Marketwired - April 06, 2015) - Long-term analysis of Radiation Therapy Oncology Group (RTOG) 9903 demonstrates that the addition of erythropoietin (EPO) did not improve local-regional control for anemic patients with head and neck squamous cell carcinoma (HNSCCa) who receive radiation therapy or chemoradiation, according to a study published in the April 1, 2015 issue of the International Journal of Radiation Oncology - Biology - Physics (Red Journal), the official scientific journal of the American Society for Radiation Oncology (ASTRO). This study is a long-term analysis of RTOG 9903, originally published in 2007[1], to determine if there were additional failures, second primaries and/or toxicities at a longer follow-up of eight years.
RTOG 9903, an open-label, Phase 3 randomized trial, examined if the addition of EPO, which stimulates the body's bone marrow to increase red blood cell production to prevent and to treat anemia, to radiation therapy would improve disease control in anemic patients with HNSCCa. The study accrued 148 patients from June 2000 to November 19, 2003, and fifty-four cancer centers participated in the trial. Eligible patients had HNSCCa of the oral cavity, oropharynx, hypopharynx or larynx; had a Zubrod performance status of zero to two (the Zubrod score indicates a patient's health status from zero to four, with zero indicating a patient is "fully active, able to carry on all pre-disease activities without restriction" and four indicating a patient is "completely disabled, cannot carry on any self-care, totally confined to bed or chair"); and hemoglobin levels less than or equal to 13.5 g/dL for males and less than or equal to 12.5 g/dL for females. After enrollment in the study, four patients were considered ineligible, and three patients withdrew from the trial.
Of the 141 patients included in the study, 69 were randomized to receive radiation therapy or chemotherapy plus radiation, and 72 were randomized to receive radiation therapy or chemotherapy plus radiation with EPO. Patients randomized to receive EPO received the first dose seven to 10 days prior to beginning radiation therapy, and then received EPO in a weekly dose of 40,000 units throughout treatment, unless hemoglobin levels exceeded 16 g/dL for males or 14 g/dL for females. Patients whose hemoglobin levels did not increase 1 g/dL or more after four doses of EPO received a dose increase to 60,000 units.
During treatment, patients were evaluated weekly for toxicities and review of their complete blood count. Follow-up was conducted at two and four weeks after treatment was completed, then every three months for the first two years post-treatment, every six months for the next three years and annually thereafter. For this long-term analysis, the median follow-up for surviving patients was 7.95 years (range 1.66 to 10.08 years) and 3.33 years for all patients (range 0.03 to 10.08 years).
This new analysis of RTOG 9903 found that at five-year follow-up, the local-regional failure rate was 39.4 percent for patients who received radiation therapy or chemoradiation without EPO and 46.2 percent for patients who received EPO (Hazard Ratio (HR) 1.27 on univariate analysis and 1.40 on multivariate analysis). The five-year local-regional progression-free survival rate was 37.6 percent for patients who did not receive EPO and 31.5 percent for patients who received EPO (HR 1.28 on univariate analysis and 1.39 on multivariate analysis). The five-year overall survival rate was 38.2 percent for patients who did not receive EPO and 36.9 percent for patients who received EPO (HR 1.13 on univariate analysis and 1.23 on multivariate analysis). The five-year distant metastases rate was 14.5 percent for patients who did not receive EPO and 15.6 percent for patients who received EPO (HR 1.03 on univariate analysis and 1.07 on multivariate analysis). The confidence interval for all measures was 95 percent. None of the differences were statistically significant; however, the HR in this long-term follow-up demonstrated improved outcomes for the patients who did not receive EPO.
"It is well-known that cancer patients with anemia (low hemoglobin) have lower cure rates than patients with normal hemoglobin levels. RTOG 9903 was aimed at improving the outcomes of anemic patients with head and neck squamous cell carcinoma by restoring their hemoglobin levels to normal," said George Shenouda, MD, lead author of the study and an associate professor of oncology and otolaryngology at McGill University Health Centre in Montral. "The initial analysis of the results was unexpected and led to the study's early closure because of a possible detrimental effect of EPO. While EPO improved hemoglobin levels, the control rates were not similarly improved. This long-term analysis confirms that EPO is not the appropriate treatment option for our anemic HNSCCa cancer patients. It is important for us to be aware that EPO is a growth factor and as such, may stimulate the growth of cancer cells, resulting in decreased tumor control. Carefully designed clinical trials are required to address how to treat anemia in our cancer patients."
An accompanying editorial from Todd A. Aguilera, MD, PhD, and Amato J. Giaccia, PhD, also published in the April 1 issue of the Red Journal, examines the implications of the study and the need to address tumor hypoxia in future clinical trials.
For a copy of the study manuscript, contact ASTRO's Press Office at press@astro.org. For more information about the Red Journal, visit http://www.redjournal.org.
[1] Machtay M, Pajak T, Suntharalingam M, et al. Radiotherapy with or without erythropoietin for anemic patients with head and neck cancer: A randomized trial of the Radiation Therapy Oncology Group (RTOG 9903). Int J Rad Oncol Biol Phys 2007; 69: 1008-1017.
Link:
Contact Information
Available for logged-in reporters only
Newswise Fairfax, Va., April 6, 2015Long-term analysis of Radiation Therapy Oncology Group (RTOG) 9903 demonstrates that the addition of erythropoietin (EPO) did not improve local-regional control for anemic patients with head and neck squamous cell carcinoma (HNSCCa) who receive radiation therapy or chemoradiation, according to a study published in the April 1, 2015 issue of the International Journal of Radiation Oncology Biology Physics (Red Journal), the official scientific journal of the American Society for Radiation Oncology (ASTRO). This study is a long-term analysis of RTOG 9903, originally published in 2007[1], to determine if there were additional failures, second primaries and/or toxicities at a longer follow-up of eight years.
RTOG 9903, an open-label, Phase 3 randomized trial, examined if the addition of EPO, which stimulates the bodys bone marrow to increase red blood cell production to prevent and to treat anemia, to radiation therapy would improve disease control in anemic patients with HNSCCa. The study accrued 148 patients from June 2000 to November 19, 2003, and fifty-four cancer centers participated in the trial. Eligible patients had HNSCCa of the oral cavity, oropharynx, hypopharynx or larynx; had a Zubrod performance status of zero to two (the Zubrod score indicates a patients health status from zero to four, with zero indicating a patient is fully active, able to carry on all pre-disease activities without restriction and four indicating a patient is completely disabled, cannot carry on any self-care, totally confined to bed or chair); and hemoglobin levels 13.5 g/dL for males and 12.5 g/dL for females. After enrollment in the study, four patients were considered ineligible, and three patients withdrew from the trial.
Of the 141 patients included in the study, 69 were randomized to receive radiation therapy or chemotherapy plus radiation, and 72 were randomized to receive radiation therapy or chemotherapy plus radiation with EPO. Patients randomized to receive EPO received the first dose seven to 10 days prior to beginning radiation therapy, and then received EPO in a weekly dose of 40,000 units throughout treatment, unless hemoglobin levels exceeded 16 g/dL for males or 14 g/dL for females. Patients whose hemoglobin levels did not increase 1 g/dL after four doses of EPO received a dose increase to 60,000 units.
During treatment, patients were evaluated weekly for toxicities and review of their complete blood count. Follow-up was conducted at two and four weeks after treatment was completed, then every three months for the first two years post-treatment, every six months for the next three years and annually thereafter. For this long-term analysis, the median follow-up for surviving patients was 7.95 years (range 1.66 to 10.08 years) and 3.33 years for all patients (range 0.03 to 10.08 years).
This new analysis of RTOG 9903 found that at five-year follow-up, the local-regional failure rate was 39.4 percent for patients who received radiation therapy or chemoradiation without EPO and 46.2 percent for patients who received EPO (Hazard Ratio (HR) 1.27 on univariate analysis and 1.40 on multivariate analysis). The five-year local-regional progression-free survival rate was 37.6 percent for patients who did not receive EPO and 31.5 percent for patients who received EPO (HR 1.28 on univariate analysis and 1.39 on multivariate analysis). The five-year overall survival rate was 38.2 percent for patients who did not receive EPO and 36.9 percent for patients who received EPO (HR 1.13 on univariate analysis and 1.23 on multivariate analysis). The five-year distant metastases rate was 14.5 percent for patients who did not receive EPO and 15.6 percent for patients who received EPO (HR 1.03 on univariate analysis and 1.07 on multivariate analysis). The confidence interval for all measures was 95 percent. None of the differences were statistically significant; however, the HR in this long-term follow-up demonstrated improved outcomes for the patients who did not receive EPO.
It is well-known that cancer patients with anemia (low hemoglobin) have lower cure rates than patients with normal hemoglobin levels. RTOG 9903 was aimed at improving the outcomes of anemic patients with head and neck squamous cell carcinoma by restoring their hemoglobin levels to normal, said George Shenouda, MD, lead author of the study and an associate professor of oncology and otolaryngology at McGill University Health Centre in Montral. The initial analysis of the results was unexpected and led to the studys early closure because of a possible detrimental effect of EPO. While EPO improved hemoglobin levels, the control rates were not similarly improved. This long-term analysis confirms that EPO is not the appropriate treatment option for our anemic HNSCCa cancer patients. It is important for us to be aware that EPO is a growth factor and as such, may stimulate the growth of cancer cells, resulting in decreased tumor control. Carefully designed clinical trials are required to address how to treat anemia in our cancer patients.
An accompanying editorial from Todd A. Aguilera, MD, PhD, and Amato J. Giaccia, PhD, also published in the April 1 issue of the Red Journal, examines the implications of the study and the need to address tumor hypoxia in future clinical trials.
For a copy of the study manuscript, contact ASTROs Press Office at press@astro.org. For more information about the Red Journal, visit http://www.redjournal.org.
More:
Fairfax, Va., April 6, 2015--Long-term analysis of Radiation Therapy Oncology Group (RTOG) 9903 demonstrates that the addition of erythropoietin (EPO) did not improve local-regional control for anemic patients with head and neck squamous cell carcinoma (HNSCCa) who receive radiation therapy or chemoradiation, according to a study published in the April 1, 2015 issue of the International Journal of Radiation Oncology * Biology * Physics (Red Journal), the official scientific journal of the American Society for Radiation Oncology (ASTRO). This study is a long-term analysis of RTOG 9903, originally published in 2007[1], to determine if there were additional failures, second primaries and/or toxicities at a longer follow-up of eight years.
RTOG 9903, an open-label, Phase 3 randomized trial, examined if the addition of EPO, which stimulates the body's bone marrow to increase red blood cell production to prevent and to treat anemia, to radiation therapy would improve disease control in anemic patients with HNSCCa. The study accrued 148 patients from June 2000 to November 19, 2003, and fifty-four cancer centers participated in the trial. Eligible patients had HNSCCa of the oral cavity, oropharynx, hypopharynx or larynx; had a Zubrod performance status of zero to two (the Zubrod score indicates a patient's health status from zero to four, with zero indicating a patient is "fully active, able to carry on all pre-disease activities without restriction" and four indicating a patient is "completely disabled, cannot carry on any self-care, totally confined to bed or chair"); and hemoglobin levels ?13.5 g/dL for males and ?12.5 g/dL for females. After enrollment in the study, four patients were considered ineligible, and three patients withdrew from the trial.
Of the 141 patients included in the study, 69 were randomized to receive radiation therapy or chemotherapy plus radiation, and 72 were randomized to receive radiation therapy or chemotherapy plus radiation with EPO. Patients randomized to receive EPO received the first dose seven to 10 days prior to beginning radiation therapy, and then received EPO in a weekly dose of 40,000 units throughout treatment, unless hemoglobin levels exceeded 16 g/dL for males or 14 g/dL for females. Patients whose hemoglobin levels did not increase ?1 g/dL after four doses of EPO received a dose increase to 60,000 units.
During treatment, patients were evaluated weekly for toxicities and review of their complete blood count. Follow-up was conducted at two and four weeks after treatment was completed, then every three months for the first two years post-treatment, every six months for the next three years and annually thereafter. For this long-term analysis, the median follow-up for surviving patients was 7.95 years (range 1.66 to 10.08 years) and 3.33 years for all patients (range 0.03 to 10.08 years).
This new analysis of RTOG 9903 found that at five-year follow-up, the local-regional failure rate was 39.4 percent for patients who received radiation therapy or chemoradiation without EPO and 46.2 percent for patients who received EPO (Hazard Ratio (HR) 1.27 on univariate analysis and 1.40 on multivariate analysis). The five-year local-regional progression-free survival rate was 37.6 percent for patients who did not receive EPO and 31.5 percent for patients who received EPO (HR 1.28 on univariate analysis and 1.39 on multivariate analysis). The five-year overall survival rate was 38.2 percent for patients who did not receive EPO and 36.9 percent for patients who received EPO (HR 1.13 on univariate analysis and 1.23 on multivariate analysis). The five-year distant metastases rate was 14.5 percent for patients who did not receive EPO and 15.6 percent for patients who received EPO (HR 1.03 on univariate analysis and 1.07 on multivariate analysis). The confidence interval for all measures was 95 percent. None of the differences were statistically significant; however, the HR in this long-term follow-up demonstrated improved outcomes for the patients who did not receive EPO.
"It is well-known that cancer patients with anemia (low hemoglobin) have lower cure rates than patients with normal hemoglobin levels. RTOG 9903 was aimed at improving the outcomes of anemic patients with head and neck squamous cell carcinoma by restoring their hemoglobin levels to normal," said George Shenouda, MD, lead author of the study and an associate professor of oncology and otolaryngology at McGill University Health Centre in Montreal. "The initial analysis of the results was unexpected and led to the study's early closure because of a possible detrimental effect of EPO. While EPO improved hemoglobin levels, the control rates were not similarly improved. This long-term analysis confirms that EPO is not the appropriate treatment option for our anemic HNSCCa cancer patients. It is important for us to be aware that EPO is a growth factor and as such, may stimulate the growth of cancer cells, resulting in decreased tumor control. Carefully designed clinical trials are required to address how to treat anemia in our cancer patients."
An accompanying editorial from Todd A. Aguilera, MD, PhD, and Amato J. Giaccia, PhD, also published in the April 1 issue of the Red Journal, examines the implications of the study and the need to address tumor hypoxia in future clinical trials.
###
For a copy of the study manuscript, contact ASTRO's Press Office at press@astro.org. For more information about the Red Journal, visit http://www.redjournal.org.
[1] Machtay M, Pajak T, Suntharalingam M, et al. Radiotherapy with or without erythropoietin for anemic patients with head and neck cancer: A randomized trial of the Radiation Therapy Oncology Group (RTOG 9903). Int J Rad Oncol Biol Phys 2007; 69: 1008-1017.
Excerpt from:
The Fall [7]
Thrak brings to you in this gameplay an awesome little game called The Fall. Made by a little game studio called Over The Moon Games, in this Let #39;s Play we take on the role of ARID, the artificial...
By: Thrak
Originally posted here:
By Brennan White
It is the obvious which is so difficult to see most of the time. People say Its as plain as the nose on your face. But how much of the nose on your face can you see, unless someone holds a mirror up to you? -Isaac Asimov, fromI, Robot
Some great minds, includingElon Musk, are clearly worried about Artificial Intelligence (AI). And with the recent innovationslikeGoogles self-driving car, the Hong Kong metro automating its own maintenance, and computers that are able to read human emotion, this fear is understandable.
Technology is finally catching up to science fiction but business leaders who wait until humanoid robots are walking around to begin implementing AI in their businesswill have missed the boat and let their competitors eat their lunch. With so many new developments in AI, the conscientious business leader should be thinking about how AI will impact their business today.
AIIs Already Here
Sci-fi has us looking for the wrong signs for the arrival of AI (e.g. C-3POs, Marvins, Hals). Much more immediate (and some may argue more impressive) achievements are largely left out of these stories. Having a computer pass the Turing test would certainly be a massive event. But ishavinga computer emulating humans the sign we should be waiting for?
Einstein supposedly said, If you judge a fish by its ability to climb a tree, it will live its whole life believing that it is stupid. Are webeing a bit shortsighted by focusing on how quickly computers can become like us when computers are already far better at doing many things?
In Hong Kong and Mountain View, there is a much more important message: AIis already here. Its arriving almost invisibly. Its happening in many, if not most, industries. From the drones that you fly to the cars that will soon be driving you, companies are putting software to work doing what software does best: intelligently automating large data sets to make timely decisions more accurately and reliably than we ever could. They areremoving work from human minds and hands.
See the original post:
Artificial Intelligence Is Already Here, But Is Your Business Ready For It?
Peter Sherrard via Getty Images
Could machines that think someday pose an existential threat to humanity? Some big names in science and tech seem to think so--Stephen Hawking, for one--and they've issued grave warnings about the looming threat of artificial intelligence.
Other experts are less concerned, saying all we have to do to prevent a robot apocalypse is to unplug them.
And then there are those who take a middle position, calling for more research and development to ensure that we "reap the benefits" of A.I. while "avoiding potential pitfalls," as one group of scientists said recently in an open letter.
What do you think? Should we be worried? Scroll down to check out some points of view, and then pick which side you're on (don't worry, we won't tell the bots).
(Credit: Bloomberg via Getty Images)
(Credit: FOX via Getty Images)
(Credit: Joel Saget via Getty Images)
(Credit: Carnegie Mellon University)
(Credit: AFP via Getty Images)
Continue reading here:
Should We Fear Artificial Intelligence? The Experts Can't ...
One of the keys to unlocking artificial intelligence will be to figure out why biological brains are so good at remembering old skillseven when learning new things.
Imagine if every time you learned something new, you completely forgot how to do a thing you'd already learned.
Finally figured out that taxi-hailing whistle? Now you can't tie your shoes anymore. Learn how to moonwalk; forget how to play the violin. Humans do forget skills, of course, but it usually happens gradually.
Computers forget what they know more dramatically. Learning cannibalizes knowledge. As soon as a new skill is learned, old skills are crowded out. It's a problem computer scientists call "catastrophic forgetting." And it happens because computer brains often rewire themselvesforging new and different connections across neural pathwaysevery time they learn. This makes it hard for a computer to retain old lessons, but also to learn tasks that require a sequence of steps.
"Researchers will need to solve this problem of catastrophic forgetting for us to get anywhere in terms of producing artificially intelligent computers and robots," said Jeff Clune, an assistant professor of computer science at the University of Wyoming. "Until we do, machines will be mostly one-trick ponies."
Catastrophic forgetting also stands in the way of one of the long-standing goals for artificial intelligence: to create computers that can compartmentalize different skills in order to solve diverse problems.
So what would it take for a computer brain to retain what it knows, even as it learns new things? That was the question Clune had when he and his colleagues set out to make an artificial brain act more like a human one. Their central idea: See if you can get a computer to organizeand preservewhat it knows within distinct modules of the brain, rather than overwriting what it knows every time it learns something new.
"Biological brains exhibit a high degree of modularity, meaning they contain clusters of neurons with high degrees of connectivity within clusters, but low degrees of connectivity between clusters," the team explained in a video about their research, which was published last week in the journal PLoS Computational Biology.
In humans and animals, brain modularity evolved as the optimal way to organize neural connections. That's because natural selection arranges the brain to minimize the costs associated with building, maintaining, and housing broader connections. "It is an interesting question as to how evolution solved this problem," Clune told me. "How did it figure out how to allow animals, including us, to learn a new skill without overwriting the knowledge of a previously learned skill?"
In order to encourage modularity in a computer's brain, researchers incorporated what they call "connection costs"essentially showing the computer that modularity is preferable. Then they measured the extent to which a computer remembered an old skill once it learned a new one.
Original post:
British actor of Indian descent Dev Patel feels that he bagged the role in sci-fi entertainer "Chappie" to add an Indian appeal to the film on artificial intelligence.
With a futuristic setting, the film takes cinema-goers to a world where crime is patrolled by an oppressive mechanised police force. It narrates a story of a police droid, Chappie, which is stolen and is re-programmed, making him the first robot with the ability to think and feel for himself. The film highlights measures taken by humans to safeguard their existence.
The film, which also stars Sigourney Weaver and Hugh Jackman, will release in India on March 13. And Dev hopes audience "really respond to the film well" and "find it entertaining".
Talking about his character -- Deon Wilson, Dev said: " He's a young guy who lives a reclusive lifestyle, and happens to be a genius from Oxford in London. But he doesn't care about violence and robots that can fight, his real objective is to find a companion and to find a robot that can feel.
"So he goes and pitches in about the idea, but is ridiculed by his boss. He then decides to steal a droid and put a chip of artificial intelligence in it to make a artificial intelligent robot."
The 24-year-old actor seems to be a fan of Robot Maid from "Richie Rich" cartoon as he fancies a robot who can help him with his daily chores.
"I would love a robot that could clean my bedroom, do dishes, the laundry, cut my grass. That would be just lovely," he said.
Originally posted here:
HOUSTON, April 3, 2015 /PRNewswire/ --InTech Aerospace, a steadily growing aviation technical services firm specialized in commercial and military airplane interiors and components, has become a classic entrepreneurial success story in Houston, Texas.The company has more than doubled in size in just the past three years. Actually, it's a growth story with multiple chapters over three decades.
InTech Aerospace can trace its predecessors' history through several earlier incarnations under previous owners, matched closely to the twists and turns, ups and downs of the airlines industry. In the 1980's, the company's first roots were created in the leather interiors cut-and-sew business supporting a fast-growing upstart airline. That first chapter grew dramatically and the company was sold to a large aerospace conglomerate. Later in the 1990's, some of the core team re-assembled under the enlightened ownership of the vice-chairman of a major airline, who built the company back to considerable scale, still specialized in aviation interiors. He eventually sold that business in the early 2000's to a regional airline, which turned it into a multi-divisional aircraft services business unit working mostly for its own in-house fleet. Strategies changed and the airline decided years later to sell the Houston division in 2011 to its leadership team, who then rapidly rebuilt InTech Aerospace back once again to an impressive array of technical capabilities and steady growth. Some of the original craftsmen and seamstresses from the earlier chapters in the 1980's and 1990's remain at InTech Aerospace to this day.
Today in 2015, the story continues. And in this newest chapter, InTech Aerospace finds itself in a period of unprecedented growth in the commercial airliner fleets. The airlines' fleets of large and regional planes are expected to double in their numbers in the next 20 years (forecasts by Boeing and Airbus), and interiors tend to wear out with heavy use, requiring periodic overhaul and upgrade. Published reports recently cited over $4 Trillion in new orders for commercial planes through the year 2033, and all of those planes (which will fly for 30 years or more) represent an "Installed Base" of many millions of man-hours of required repairs and refurbishments.That aftermarket phenomenon of recurring repairs is where InTech predicts its most aggressive growth in the next 5 to 10 years.
Performing a variety of overhaul and retrofit chores chiefly on aircraft interiors and related components, InTech Aerospace today enjoys a client list that includes regional airlines, mainline carriers, large OEM's, aircraft leasing companies, and major MRO facilities.Known as the "interior experts," Intech Aerospace has teams of highly experienced craftspeople in these areas:
Todd Wilkinson, President of InTech Aerospace, said: "Our airlines and MRO clients know that InTech can deliver excellent quality, on-time delivery, and an absolute cost advantage for anything they need inside the airplane. We are highly specialized on all interior components, front to back. And, our remote Interior Remove and Install Teams are saving MRO and airline maintenance locations valuable time and labor with InTech completing the installation. This allows their valuable technicians to focus on other areas of aircraft maintenance tasks.Our quality is assured through the scores of superbly trained and deeply experienced technical employees who call InTech home."
InTech Aerospace intends to invest for growth in each of its lines of business, and expand geographically, to keep pace with rising industry trends. Riding the growth wave as this story continues.
For more information: http://www.intechaero.com. InTech Aerospace LLC, 4750 World Houston Parkway, Suite 100, Houston, TX 77032 PH (281) 810-4400.
Forward Looking Statements: The Company from time to time may discuss forward-looking information. Except for factual historical information, all forward looking statements are estimates by the Company's management and are subject to various risks and uncertainties that are beyond the Company's control and may cause actual results to differ materially from management's expectations.
Logo - http://photos.prnewswire.com/prnh/20150403/196537LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/intech-aerospace--riding-the-growth-wave-on-commercial-aircraft-300060989.html
Originally posted here:
InTech Aerospace: Riding the Growth Wave on Commercial Aircraft
Is the Do-It-Yourself Retirement Model Failing Us?
401(k) auto-enrollment and auto-escalation programs have made a big difference, but too many retirement savers are still being left behind, says behavioral science and economics professor Richard...
By: Morningstar, Inc.
Read the original post:
Is the Do-It-Yourself Retirement Model Failing Us? - Video
CONWAY -- The bionic hand fashioned by 14-year-old Destany Ballard can hold and pick up objects that are as heavy as 2 pounds.
Relying on rubber bands, sturdy plastic bars and a simple system of pulling the two with a chain, the mechanical hand can be made at home at a low cost, Destany said, which could help a person who can't afford higher-technology prosthetics.
Destany, a freshman at Buffalo Island Central High School in Monette in northeast Arkansas, presented the hand Saturday at the Arkansas State Science and Engineering Fair held at the University of Central Arkansas in Conway. She was among about 250 high school students who displayed their theories and inventions.
Students mingled with new friends and their parents on the Jeff Farris Health and Physical Education Center gym floor, which was covered Saturday in tables and colorful tri-fold poster boards. The students ate cookies and awaited a decision about who would be selected to take part in the national science fair competition later this year.
The projects spanned the vast imaginations of Arkansas high school students: a behavioral study of what motivated people to sleep more hours at night, a somewhat stomach-turning study on the decomposition of ants and their release of oleic acid, and the ambitious "Enhancement of the Photocurrent Response of Tungsten Nano-Structures Using an Indium Oxide Coating," a project undertaken by three Little Rock Central High School students.
The event also had a robot, designed to follow lines and make turns while propelling itself.
Destany came up with the idea for a bionic hand last year after realizing that many soldiers return from combat having lost limbs. Concerned about the cost of replacing limbs, Destany decided to see what she could do to help.
"People spend a lot of money on hands," she said.
Since January, Destany has spent Tuesdays and Thursdays after school constructing the hand. Next year, Destany wants to create a voice-command system that would trigger the mechanical fingers to move.
Other science and engineering fair entrants have spent multiple years putting together their projects.
See original here:
Science fair displays students' ingenuity
Miami, FL (PRWEB) April 06, 2015
Regenestem Network, a subsidiary of the Global Stem Cells Group, has announced plans to attend the 23rd Annual World Congress on Anti-Aging Medicine (a4m) at the Diplomat Resort and Spa in Hollywood, Fla. Hosted by the American Academy of Anti-aging Medicine, the conference will be attended by physicians and medical practitioners from around the world.
Regenestem Network plans to showcase its upcoming stem cell training course, Adipose Derived and Bone Marrow Stem Cell course, with classes scheduled to be held May 9-10 and June 15-16, 2015 in Miami. The intensive, two-day course covers the latest technology and procedures in adipose and bone marrow stem cell therapies. Participants learn skills that can be used in their own practice and for career advancement.
A4m Conference Keynote speakers include Daniel G. Amen, MD, David Perlmutter, MD, FACN, ABIHM, and Gary Small, MD. All three will focus on disease prevention and optimized health through a proactive treatment approach. These world-renown speakers are scheduled to deliver insightful presentations, the latest research and breakthrough therapies in anti-aging medicine.
To learn more about the 23rd Annual World Congress on Anti-Aging Medicine, visit the a4m website. For more information on the Regenestem Network, visit the website at regenestemnetwork.com. For more information on the stem cell training classes, visit the http://www.stemcelltraining.net website, email bnovas(at)regenestem(dot)com, or call 849.943.2988.
About Regenestem Network:
Regenestem Network, a division of the Global Stem Cells Group, Inc., is an international medical practice association committed to researching and producing comprehensive stem cell treatments for patients worldwide. Having assembled a highly qualified staff of medical specialistsprofessionals trained in the latest cutting-edge techniques in cellular medicineRegenestem continues to be a leader in delivering the latest protocols in the adult stem cell arena. Global Stem Cells Group and Regenestem Network are expanding the companys clinical presence worldwide by partnering with experienced and qualified regenerative medicine physicians to open new clinics licensed and developed under the Regenestem banner. In 2014, Global Stem Cells Group expanded the Regenestem Networks global presence to 20 countries.
Regenestem offers stem cell treatments to help treat a variety of diseases and conditions including arthritis, autism, chronic obstructive pulmonary disease (COPD), diabetes, and pain due to injuries at various facilities worldwide. Regenestem Oaxaca will have an international staff experienced in administering the latest in cellular therapies.
Regenestem is certified for the medical tourism market, and staff physicians are board-certified or board-eligible. Regenestem clinics provide services in more than 10 specialties, attracting patients from the United States and around the world.
About the Global Stem Cell Group:
The rest is here:
Regenestem Network Announces Plans to Attend the 23rd Annual World Congress on Anti-Aging Medicine May 7-9, 2015
Life Under Atheism = Death
How Many People Did Joseph Stalin Kill? In February 1989, two years before the fall of the Soviet Union, a research paper by Georgian historian Roy Aleksandrovich Medvedev published in the...
By: Dave Flang
See the original post:
GERMANWING AIRLINER DOWNED BY US AIR FORCE HIGH ENERGY LIQUID LASER TEST; NATO WAR GAMES
No, the co-pilot didn #39;t commit suicide, and homicide. Subscribe to R Klaus; links are below. https://syrianfreepress.wordpress.com/2015/03/28/report-44141/ https://www.youtube.com/watch?v=SgBbnQ...
By: KafkaWinstonWorld
More here:
GERMANWING AIRLINER DOWNED BY US AIR FORCE HIGH ENERGY LIQUID LASER TEST; NATO WAR GAMES - Video